Journal Article DKFZ-2026-02014

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Case Report: Non-invasive [89Zr]Zr-DFO-trastuzumab positron emission tomography in the multimodal characterisation of platinum-resistant high-grade serous ovarian cancer.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2026
Frontiers Media Lausanne

Frontiers in nuclear medicine 6, 1832138 () [10.3389/fnume.2026.1832138]
 GO

Abstract: We report a case that combines several aspects of molecular diagnostics and clinical follow-up with innovative imaging of [89Zr]Zr-DFO-trastuzumab positron emission computed tomography (PET/CT) to depict human epidermal growth factor receptor 2 (HER2)-targeted tracer uptake in several metastatic sites in advanced platinum-resistant high-grade serous ovarian cancer (HGSOC). A 74-year-old woman underwent this procedure, and PET/CT images were interpreted alongside conventional biomarkers [CA125 and immunohistochemistry (IHC)] and contrast-enhanced computed tomography (CE-CT). PET imaging revealed intense tracer uptake in the primary ovarian tumour site (SUVratio 13.8), with corresponding HER2 + expression (3+) observed on the IHC of the primary tumour. Moreover, moderate uptake was observed in abdominal wall metastases (SUVratio 3.6) and near-background uptake in hepatic lesions (SUVratio 1.6), consistent with image-suggestive spatial heterogeneity in HER2-targeted tracer uptake. CA125 measurements corroborated early biochemical response, with values declining from 676 to 254 U/mL after six weeks of trastuzumab deruxtecan (T-DXd) treatment as third-line therapy. Follow-up CE-CT showed qualitative regression of [89Zr]Zr-DFO-trastuzumab-avid lesions, despite non-measurable disease by RECIST and a subsequent CE-CT imaging after 20 weeks demonstrated a mixed response pattern, without a clear relationship to pre-T-DXd [89Zr]Zr-DFO-trastuzumab uptake. This case study illustrates how integrating non-invasive [89Zr]Zr-DFO-trastuzumab PET molecular imaging with conventional radiology, IHC, and biochemical markers within the clinical pathway may support individualised therapeutic decision-making.

Keyword(s): HER2 overexpression ; [89Zr]Zr-DFO-trastuzumab ; case report ; high-grade serous ovarian cancer ; multimodality

Classification:

Note: #NCTZFB26#

Contributing Institute(s):
  1. Koordinierungsstelle NCT Dresden (DD04)
  2. Translationale Bildgebung in der Onkologie (DD12)
Research Program(s):
  1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026
Database coverage:
Medline ; Creative Commons Attribution CC BY (No Version) ; DOAJ ; OpenAccess ; Article Processing Charges ; DOAJ Seal ; Fees ; SCOPUS
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database
Open Access

 Record created 2026-08-14, last modified 2026-11-10


OpenAccess:
Download fulltext PDF Download fulltext PDF (PDFA)
External link:
Download fulltextFulltext by Pubmed Central
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)